SCHEMBL756286

SCHEMBL756286

Cc1cc(Oc2ccccc2)cc(C)c1C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
LTA4H P09960 2/20 0.46
TSHR P16473 1/20 0.46
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
TTR P02766 1/20 0.44
NPSR1 Q6W5P4 2/20 0.42
PGR P06401 1/20 0.41
GSTP1 P09211 1/20 0.40
SOS1 Q07889 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ERN1 O75460 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028534 0.88 LTA4H (0.44) LMNALTA4HTSHRCYP1A2POLB
SCHEMBL2028440 0.87 TTR (0.51) LMNALTA4HCYP1A2POLBCYP2C19
SCHEMBL27916443 0.82 LTA4H (0.48) LMNALTA4HTSHRHTTSMN1; SMN2
SCHEMBL2025964 0.80 PTGS1 (0.36) LMNACYP1A2POLBCYP2C19HTT
SCHEMBL2028520 0.79 LMNA (0.35) LMNACYP1A2POLBCYP2C19HTT
SCHEMBL953278 0.78 LTA4H (0.44) LMNALTA4HTSHRCYP1A2POLB
SCHEMBL9114889 0.78 LMNA (0.50) LMNALTA4HTSHRCYP1A2CYP2C19
SCHEMBL12925863 0.77 LTA4H (0.57) LTA4HTSHRHTTSMN1; SMN2KMT2A
SCHEMBL2467657 0.77 LTA4H (0.41) LMNALTA4HTSHRPOLBHTT
SCHEMBL27916454 0.77 LTA4H (0.41) LMNALTA4HTSHRHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916589-B2 Bradykinin B1-antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-12-23 US disclosed
EP-2188254-B1 NOVEL BRADYKININ B1-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2012-03-21 EP disclosed
US-20110263626-A1 NOVEL BRADYKININ B1-ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 US disclosed
EP-2188254-A1 NOVEL BRADYKININ B1-ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2010-05-26 EP disclosed
WO-2009027450-A1 NOVEL BRADYKININ B1-ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263626-A1 NOVEL BRADYKININ B1-ANTAGONISTS BDKRB1, BDKRB2, EDNRB LMNA 1305/4885LTA4H 210/4885TSHR 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.